4.6 Review

Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies

期刊

FRONTIERS IN PHYSIOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2021.593223

关键词

ACE2; coronavirus; lung; multiple organ dysfunction; pathophysiology; SARS-CoV-2; therapy; viral infection

资金

  1. Brazilian Council for Scientific and Technological Development (CNPq)
  2. Carlos Chagas Filho Rio de Janeiro State Research Foundation (FAPERJ)
  3. 2018 Gilead Sciences Research Scholars for Cystic Fibrosis

向作者/读者索取更多资源

SARS-CoV-2 is a novel coronavirus responsible for the COVID-19 pandemic, with the ability to infect human cells through binding to ACE2. This can lead to multi-organ dysfunction syndrome, highlighting the importance of understanding the virus's biology and pathogenesis for identifying effective therapies.
Severe acute respiratory disease coronavirus 2 (SARS-CoV-2, formerly 2019-nCoV) is a novel coronavirus that has rapidly disseminated worldwide, causing the coronavirus disease 2019 (COVID-19) pandemic. As of January 6th, 2021, there were over 86 million global confirmed cases, and the disease has claimed over 1.87 million lives (a similar to 2.2% case fatality rate). SARS-CoV-2 is able to infect human cells by binding its spike (S) protein to angiotensin-conversing enzyme 2 (ACE2), which is expressed abundantly in several cell types and tissues. ACE2 has extensive biological activities as a component of the renin-angiotensin-aldosterone system (RAAS) and plays a pivotal role as counter-regulator of angiotensin II (Ang II) activity by converting the latter to Ang (1-7). Virion binding to ACE2 for host cell entry leads to internalization of both via endocytosis, as well as activation of ADAM17/TACE, resulting in downregulation of ACE2 and loss of its protective actions in the lungs and other organs. Although COVID-19 was initially described as a purely respiratory disease, it is now known that infected individuals can rapidly progress to a multiple organ dysfunction syndrome. In fact, all human structures that express ACE2 are susceptible to SARS-CoV-2 infection and/or to the downstream effects of reduced ACE2 levels, namely systemic inflammation and injury. In this review, we aim to summarize the major features of SARS-CoV-2 biology and the current understanding of COVID-19 pathogenesis, as well as its clinical repercussions in the lung, heart, kidney, bowel, liver, and brain. We also highlight potential therapeutic targets and current global efforts to identify safe and effective therapies against this life-threatening condition.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据